Research analysts at Guggenheim increased their price objective on shares of Celgene Corp. (NASDAQ:CELG) from $152.00 to $176.00 in a report released on Thursday, StockRatingsNetwork.com reports. The firm currently has a “buy” rating on the stock. Guggenheim’s price objective points to a potential upside of 11.42% from the company’s current price.
Several other analysts have also recently commented on the stock. Analysts at Deutsche Bank raised their price target on shares of Celgene Corp. from $162.00 to $170.00 in a research note to investors on Thursday. They now have a “buy” rating on the stock. Separately, analysts at RBC Capital raised their price target on shares of Celgene Corp. from $150.00 to $170.00 in a research note to investors on Wednesday, October 9th. They now have an “outperform” rating on the stock. Finally, analysts at Bank of America Corp. raised their price target on shares of Celgene Corp. from $164.00 to $179.00 in a research note to investors on Tuesday, October 8th. They now have a “buy” rating on the stock. Five investment analysts have rated the stock with a hold rating and twenty-three have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $147.41.
Shares of Celgene Corp. (NASDAQ:CELG) traded down 1.27% on Thursday, hitting $157.96. 3,835,848 shares of the company’s stock traded hands. Celgene Corp. has a 52 week low of $70.42 and a 52 week high of $151.00. The stock has a 50-day moving average of $142.3 and a 200-day moving average of $125.4. The company has a market cap of $64.965 billion and a P/E ratio of 44.74.
Celgene Corp. (NASDAQ:CELG) last announced its earnings results on Thursday, October 24th. The company reported $1.56 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.54 by $0.02. The company had revenue of $1.67 billion for the quarter, compared to the consensus estimate of $1.64 billion. During the same quarter last year, the company posted $1.29 earnings per share. Celgene Corp.’s revenue was up 18.0% compared to the same quarter last year. Analysts expect that Celgene Corp. will post $5.98 EPS for the current fiscal year.
Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.